GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Gross Margin %

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Gross Margin %

: 53.98% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Amphastar Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $96.1 Mil. Amphastar Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $178.1 Mil. Therefore, Amphastar Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 53.98%.


The historical rank and industry rank for Amphastar Pharmaceuticals's Gross Margin % or its related term are showing as below:

AMPH' s Gross Margin % Range Over the Past 10 Years
Min: 24.35   Med: 40.88   Max: 54.49
Current: 54.49


During the past 13 years, the highest Gross Margin % of Amphastar Pharmaceuticals was 54.49%. The lowest was 24.35%. And the median was 40.88%.

AMPH's Gross Margin % is ranked better than
63.74% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.855 vs AMPH: 54.49

Amphastar Pharmaceuticals had a gross margin of 53.98% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Amphastar Pharmaceuticals was 8.10% per year.


Amphastar Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Amphastar Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.92 40.97 45.63 49.87 54.49

Amphastar Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.71 52.73 49.92 60.04 53.98

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals Gross Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Gross Margin % falls into.



Amphastar Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Amphastar Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=351.1 / 644.395
=(Revenue - Cost of Goods Sold) / Revenue
=(644.395 - 293.274) / 644.395
=54.49 %

Amphastar Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=96.1 / 178.105
=(Revenue - Cost of Goods Sold) / Revenue
=(178.105 - 81.965) / 178.105
=53.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Amphastar Pharmaceuticals  (NAS:AMPH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amphastar Pharmaceuticals had a gross margin of 53.98% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Amphastar Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710